TELESTA THERAPEUTICS INC T.TST

Reviews Urology 2015

[cheetio]

yep real blockbuster......ha https://www.nature.com/nrurol/journal/vaop/ncurrent/full/nrurol.2015.58.html

[terr2]

So with respect to the management we currently are blessed with. We (TST) are still lost in the fog. What a crying shame.

[sometoast]

I am not sure that I follow your concern, Cheetio and Terr2. The review concludes that BCG is the gold standard treatment but that reducing toxicity needs to be improved. The review cites the TST study as a possible key to this: "One approach to address the toxicity observed with BCG treatment is the use of nonlive-BCG immunotherapy. For example, BCG cell wall components have been

[1wascallywabbit]

Looks like a great piece promoting the efficacy and non-toxicity of MCNA. They didn't read it. 

[cashmeout]

There is a bcg article in the march 2015 issue, it has a small plug for mcna at the end. The mcna article is in the april 2015.  Fork out the 30usd and have a read.  I'll happily email anyone that wants the article.

[beechguy]

Finally someone else singing my tune. "In patients with papillary-only tumours (**90% of NMIBC patients**), MCNA was even more effective with rates of 35.1% and 32.2% at 1 year and 2 years, respectively." First line therapy - off label should be quickly adopted. I think a CRR to the tune of

[cheetio]

fda toxicity = no greenlight